Topotecan weekly bolus chemotherapy for relapsed platinum-sensitive ovarian and peritoneal cancers

OBJECTIVE: Topotecan at a dose of 1.5 mg/m(2) on days 1 to 5 of a 21-day cycle is an approved therapy for recurrent ovarian cancer. However, heavily pretreated patients may be predisposed to hematologic adverse events. This prospective study, therefore, investigates the safety and efficacy of an alt...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Morris, Robert, Alvarez, Ronald D., Andrews, Stephen, Malone, John, Bryant, Christopher, Heilbrun, Lance K., Smith, Daryn, Schimp, Veronica, Munkarah, Adnan
Médium: Artigo
Jazyk:Inglês
Vydáno: 2008
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3865862/
https://ncbi.nlm.nih.gov/pubmed/18410954
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2008.02.028
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky